A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran
Variances in the patients’ outcomes have been a well-documented challenge in anticoagulant therapy. A clinical encounter with a thromboembolic or a hemorrhagic event, due to subtherapeutic or adverse effects of an anticoagulant, is often managed by switching the anticoagulant agent into another, whi...
-д хадгалсан:
| Үндсэн зохиолчид: | , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Цуврал: | Medical Journal of Babylon |
| Нөхцлүүд: | |
| Онлайн хандалт: | http://www.medjbabylon.org/article.asp?issn=1812-156X;year=2022;volume=19;issue=3;spage=332;epage=340;aulast=Abd |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|